Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07313852 · ClinicalTrials.gov registry record · Phase 1
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT07313852: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07313852 is a Phase 1 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07313852, a Phase 1 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Primary Outcome
To establish the MTD in phase 1 part of the study
Interventions
- DRUG Blinatumomab Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
What is known before NCT07313852 opens enrollment
NCT07313852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Blinatumomab Injection is the first listed.
NCT07313852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07313852 about?
NCT07313852 is a clinical study titled "A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia". The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
What is the current status of trial NCT07313852?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2026-06. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07313852?
The interventions under investigation include: Blinatumomab Injection (DRUG).
Who is sponsoring clinical trial NCT07313852?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07313852's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia